How much is the latest price of Dacomitinib in 2024?

Dacomitinib (Dacomitinib) is an oral, second-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) primarily used to treat non-small cell lung cancer (NSCLC). EGFR is an important cell signaling molecule, and its mutations play a role in driving the occurrence and development of cancer in many NSCLC patients. Dacomitinib prevents the proliferation and survival of tumor cells by irreversibly inhibiting EGFR and its common mutations.

Dacomitinib is now available in China and has been included in the medical insurance directory, and patients can purchase it domestically. The price of the drug, which is 15 mg and 30 pills, is about more than one thousand yuan. For specific price information and medical insurance reimbursement details, please consult the pharmacy of your local hospital. In comparison, the price of Pfizer's original drug on the European market is as high as more than 20,000 yuan, which seems relatively expensive. In foreign countries, the relatively affordable generic drugs produced in Laos are 45mg30 capsules. The price is only about a few thousand yuan, which is three times lower than the domestic price, and its drug ingredients are basically the same as the original drugs.

The development background of dacomitinib is based on the resistance problems that occurred during the use of first-generation EGFR-TKIs, such as gefitinib (Gefitinib) and erlotinib (Erlotinib). Although the first-generation drugs have improved the survival and quality of life of patients, during the treatment process, patients often develop drug-resistant mutations such as EGFR T790M, which greatly reduces the efficacy of the drugs. To overcome these resistances, dacomitinib was developed as a second-generation EGFR-TKI.

Dacomitinib irreversibly binds to and inhibits the kinase activity of EGFR, not only against common EGFR mutations such as L858R and Exon 19Deletions are effective and can also suppress some rare types of mutations. Its irreversible combination makes the drug more durable and more effective in inhibiting the growth of tumor cells. In 2018, the U.S. Food and Drug Administration (FDA) approved dacomitinib (dacomitinib) for the treatment of patients with metastatic non-small cell lung cancer with EGFR mutations, marking the important clinical status of this drug.